Tags

Type your tag names separated by a space and hit enter

Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies.
Curr Diabetes Rev. 2020; 16(7):750-758.CD

Abstract

INTRODUCTION

Obesity shows a multifactorial disease and presents a serious public health problem, with an alarming epidemic character. According to NHANES (National Health and Nutrition Examination Survey) from 2015 to 2016, 39.6% of American adults and 18.5% of young people were obese and 7.7% of adults and 5.6% of young people had severe obesity. Brazil ranks fifth in the world ranking, with about 18 million people reaching up to 70 million overweight individuals. Despite shortterm weight loss with diet and exercise, weight regain continues to be a concern. Anti-obesity drugs, such as Sibutramine (SIB), Phentermine (PHEN), Fenproporex (FEN), Mazindol (MAZ), Amfepramone (AMFE) and Orlistat (ORL) may play a role in weight reduction in patients whose condition is refractory to non- and maintenance of weight loss.

OBJECTIVE

A systematic review followed by meta-analysis of randomized clinical trials over the past five years to explore the efficacy and safety of anorexigenic drugs for weight reduction and consequent treatment of obesity.

METHODS

The search strategy in MEDLINE / Pubmed, Web of Science, ScienceDirect Journals (Elsevier), Scopus (Elsevier), OneFile (Gale) is as follows : - search for mesh terms (Sibutramine, Phentermine, Fenproporex, Mazindol, Amfepramone , Orlistat, Weight loss, Safety), and the use of booleans "and" between mesh terms and "or" among historical findings.

RESULTS

It was observed that in the last five years of randomized studies no significant general complications were found, with only 5.7%. The mean overall weight loss was 6.18 (± 2.8) kg in the mean time of 12 months. The overall success rate among these drugs was 80.18%. The p-value values did not present a significant statistical difference, being p <0.05 within each drug group analyzed, for both weight and success rates.

CONCLUSION

The scientific findings of randomized studies on the use of anorexigenic drugs to treat obesity have shown safety and efficiency in the last five years, with a reasonable weight loss and no significant complications.

Authors+Show Affiliations

Associacao Brasileira de Nutrologia (ABRAN)/Brazilian Association of Nutrology, Catanduva/SP, Rua Belo Horizonte, 909 - Centro, Catanduva SP, Brazil.Associacao Brasileira de Nutrologia (ABRAN)/Brazilian Association of Nutrology, Catanduva/SP, Rua Belo Horizonte, 909 - Centro, Catanduva SP, Brazil.Post Graduate and Continuing Education (Unipos), Department of Scientific Production, Street Ipiranga, 3460, Sao Jose do Rio Preto/SP, Brazil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31729302

Citation

Garcia Ramirez, Ana Valéria, et al. "Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: the Last Five Years of the Randomized Studies." Current Diabetes Reviews, vol. 16, no. 7, 2020, pp. 750-758.
Garcia Ramirez AV, Filho DR, Zotarelli Filho IJ. Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies. Curr Diabetes Rev. 2020;16(7):750-758.
Garcia Ramirez, A. V., Filho, D. R., & Zotarelli Filho, I. J. (2020). Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies. Current Diabetes Reviews, 16(7), 750-758. https://doi.org/10.2174/1573399815666191113125247
Garcia Ramirez AV, Filho DR, Zotarelli Filho IJ. Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: the Last Five Years of the Randomized Studies. Curr Diabetes Rev. 2020;16(7):750-758. PubMed PMID: 31729302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies. AU - Garcia Ramirez,Ana Valéria, AU - Filho,Durval Ribas, AU - Zotarelli Filho,Idiberto José, PY - 2019/06/04/received PY - 2019/08/13/revised PY - 2019/10/28/accepted PY - 2019/11/16/pubmed PY - 2019/11/16/medline PY - 2019/11/16/entrez KW - Anorexigenic drugs KW - complications KW - exercise KW - obesity KW - safety KW - weight loss SP - 750 EP - 758 JF - Current diabetes reviews JO - Curr Diabetes Rev VL - 16 IS - 7 N2 - INTRODUCTION: Obesity shows a multifactorial disease and presents a serious public health problem, with an alarming epidemic character. According to NHANES (National Health and Nutrition Examination Survey) from 2015 to 2016, 39.6% of American adults and 18.5% of young people were obese and 7.7% of adults and 5.6% of young people had severe obesity. Brazil ranks fifth in the world ranking, with about 18 million people reaching up to 70 million overweight individuals. Despite shortterm weight loss with diet and exercise, weight regain continues to be a concern. Anti-obesity drugs, such as Sibutramine (SIB), Phentermine (PHEN), Fenproporex (FEN), Mazindol (MAZ), Amfepramone (AMFE) and Orlistat (ORL) may play a role in weight reduction in patients whose condition is refractory to non- and maintenance of weight loss. OBJECTIVE: A systematic review followed by meta-analysis of randomized clinical trials over the past five years to explore the efficacy and safety of anorexigenic drugs for weight reduction and consequent treatment of obesity. METHODS: The search strategy in MEDLINE / Pubmed, Web of Science, ScienceDirect Journals (Elsevier), Scopus (Elsevier), OneFile (Gale) is as follows : - search for mesh terms (Sibutramine, Phentermine, Fenproporex, Mazindol, Amfepramone , Orlistat, Weight loss, Safety), and the use of booleans "and" between mesh terms and "or" among historical findings. RESULTS: It was observed that in the last five years of randomized studies no significant general complications were found, with only 5.7%. The mean overall weight loss was 6.18 (± 2.8) kg in the mean time of 12 months. The overall success rate among these drugs was 80.18%. The p-value values did not present a significant statistical difference, being p <0.05 within each drug group analyzed, for both weight and success rates. CONCLUSION: The scientific findings of randomized studies on the use of anorexigenic drugs to treat obesity have shown safety and efficiency in the last five years, with a reasonable weight loss and no significant complications. SN - 1875-6417 UR - https://www.unboundmedicine.com/medline/citation/31729302/Meta-analyses_and_approach_of_the_real_impact_of_anorexigenic_drugs_in_the_obesity_in_humans:_the_last_five_years_of_the_randomized_studies L2 - http://www.eurekaselect.com/176640/article DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.